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Abstract
The advances in biomedicine over the past decade have provided revolutionary insights into
molecules that mediate cell proliferation and differentiation. Findings on the complex
interplay of cells, growth factors, matrix molecules and cell adhesion molecules in the
process of tissue patterning have vitalized the revolutionary approach of bioregenerative
medicine and tissue engineering. Here we review the impact of recent work in this
interdisciplinary field on the treatment of musculoskeletal disorders. This novel concept
combines the transplantation of pluripotent stem cells, and the use of specifically tailored
biomaterials, arrays of bioactive molecules and gene transfer technologies to direct the
regeneration of pathologically altered musculoskeletal tissues.
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Introduction
During the past decade new and exciting strategies have
emerged that will revolutionize the treatment of patients
suffering from failure of vital structures. The science fiction
scenario of regenerating damaged organs or even creating
a completely new tissue was brought to life with the
concept of tissue engineering. The basic knowledge
gained in the fields of cell and molecular biology, combined
with the impact of biomaterial research, has provided the
essential tools to bring about a practical approach to biore-
generation. Tissue engineering procedures focus on the
delivery or in situ mobilization of cells capable of restoring
the pathologically altered architecture and function. This
approach comprises the interactive triad of responsive
cells, a supportive matrix and bioactive molecules promot-
ing differentiation and regeneration. The strategy of a
directed regeneration of musculoskeletal tissue damaged
by trauma, chronic inflammation or degeneration will per-
fectly supplement the treatment, once approved, with the
new biological therapeutics in rheumatology.
Cell transplantation
Musculoskeletal structures such as joints are composed
of various specialized mesenchymal cells, which manage
individual biomechanical requirements by a finely tuned
turnover of their extracellular matrix [1]. Tissue damage
results from a major pathological impact and inappropriate
repair. Tissue engineering techniques attempt to directArthritis Research    Vol 2 No 6 Schultz et al
and optimize the regeneration of altered tissue. Thus, non-
penetrating cartilage defects do not heal adequately,
owing to the lack of mobilization of chondrocytes from the
vicinity of the defect and the inaccessibility of chon-
droprogenitor cells from the bone marrow [2]. So far, most
approaches for tissue repair have used the transplantation
of differentiated autologous cells, obtained from biopsies
of the corresponding tissue. For cartilage repair this
approach was performed by Brittberg et al [3], who
injected a suspension of previously isolated and in vitro
amplified autologous chondrocytes under a periost flap
into the cartilage defect. The disadvantages of this proce-
dure are obvious: the limited availability of cells, the mor-
bidity at the donor site and the restricted potential for
proliferation and subsequent differentiation. Novel strate-
gies focus on the transplantation or in situ mobilization of
mesenchymal precursor or stem cells. These versatile
cells are easy to obtain, have an expanded proliferative
capacity and the potential to differentiate into bone, carti-
lage, muscle and tendon, depending on positional cues
and the corresponding microenvironment [4]. Mesenchy-
mal stem cells reside mainly within the bone marrow but
have been isolated from the connective tissue of almost
every organ, suggesting a role as a reservoir and regener-
ation pool for the various mesenchymal tissues [5].
Several experimental studies have been successfully com-
pleted to evaluate the potential of mesenchymal stem cells
for their feasibility and efficacy in healing cartilaginous,
osseous, tendon defects or even in treating genetic disor-
ders such as osteogenesis imperfecta or Duchenne’s
muscular dystrophy [6–8]. An alternate approach might
circumvent the cell transplantation procedure with a direct
stimulation and mobilization of the progenitor cells of
residual tissue. Thus, local tissue turnover and repair activ-
ity involves four steps: first, chemoattraction of mesenchy-
mal progenitor cells from resident sites such as bone
marrow and synovial membrane or distant reservoirs;
second, condensation of cells via upregulation of essential
cell adhesion molecules; third, local proliferation; fourth,
subsequent differentiation. The direction and management
of this complex process can be achieved with the con-
trolled release of individual bioactive molecules, which
might include growth factors, cytokines, cell adhesion mol-
ecules and chemokines, or a subset of these, and the use
of specially designed scaffolds guiding this process both
temporally and spatially.
Morphogenic factors
Regeneration and tissue repair seem to involve similar cellu-
lar transitional events to those observed during embryogen-
esis. However, the pace of these events in tissue
homeostasis in the adult organism is much slower, and the
decline in uncommitted progenitor cells and lack of corre-
sponding signals, prevent effective rejuvenation or complete
regeneration of the tissue. A complex network of bioactive
molecules, with emphasis on bone morphogenetic proteins
(such as BMPs 2, 4 and 7), growth and differentiation
factors (such as GDFs 5 and 6), are known to orchestrate
osteochondrogenic morphogenesis [9] as well as tissue
homeostasis [10]. However, their pattern of expression
during bone and joint disorders is still an enigma. Closely
related factors exhibit differential effects, which might be
synergistic, sequential, overlapping or antagonizing. This
might depend on the complexity of homodimerization and
heterodimerization of individual BMPs, the promiscuity of
binding to different types of receptors, or the different path-
ways of intracellular signalling [11,12]. Furthermore, matrix
molecules and membrane-bound components are likely to
modulate the activity of growth factors [13]. In view of this
confusing complexity it is obviously quite difficult to find the
right factor to initiate the effect desired. Several studies with
the incorporation of BMPs in carrier structures resulted in
better and faster healing of cartilage and bone defects [14].
However, advanced approaches will probably use a spe-
cially tailored array of bioactive factors that separately
address cell migration, proliferation, differentiation and
tissue maturation. Moreover, these aspects have to be con-
sidered during the formation of cartilage and bone trans-
plants in vitro. Bioreactors and perfusion systems closely
mimic the situation in vivo with the essential extracellular
matrix environment and biomechanical influence, and
ensure the establishment of an artificial cartilage or bone
tissue [15].
Bioartificial tissues
Specifically tailored biomaterials are crucial tools in tissue
engineering (Figure 1), which have to provide biocompati-
bility (which means not eliciting an inflammatory reaction
or immunorejection), biodegradibility and a variable
design, that depends on the biomechanical profile of the
anatomical situation in question. Moreover, they have to
ensure an adequate cell distribution, new matrix formation
and tissue integration, thus simulating an ideal embryo-like
environment. This might be achieved by solid resorbable
polymer scaffolds (polylactid acid, polyglycolic acid, poly-
ethylene or polypropylene) or other porous structures,
which could be combined with hydrogels such as
agarose, fibrin or alginate [16,17]. The encapsulation of
scaffolds with semipermeable membranes will keep syn-
thesized proteoglycans and collagens inside the tissue
and will provide additional immune protection [18]. Struc-
tural deficits of bioartificial tissues established in vitro,
including the lack of any polarization, fibril orientation and
cell orientation, might be improved with new, ‘smart’ poly-
mers. Chemical modification with the incorporation of
functional groups, side chains [the Arg-Gly-Asp (RGD)
sequence], mimetic substances, matrix proteins
(hyaluronic acid and tricalcium phosphate) or cell adhe-
sion molecules will transform simple cell carriers to
dynamic structures adapting to natural forces and require-
ments and thus guiding cell differentiation and matrix for-
mation. Combination with release systems (for examplehttp://arthritis-research.com/content/2/6/433
microspheres) for growth factors along gradients will
enhance appropriate tissue development [19].
Clinical aspects
The spectrum of clinical applications includes the repair of
critical bone defects resulting from trauma, infection, con-
genital malformation, tumour or insufficient endoprosthetic
surgery [20] and the restoration of cartilage in destructive
joint diseases or traumatic injuries. Bone reconstruction was
performed successfully with the transplantation of pluripo-
tent osteogenic cells in a polymer, collagen or ceramic scaf-
fold in several studies [21]. On the basis of the regenerative
potential of bone marrow stromal cells and periosteal cells,
the implantation of scaffolds with incorporated morphogenic
factors (transforming growth factor, BMP) indicated suffi-
cient osseous bridging and bone formation [22]. For the
replacement of joint cartilage, pressure resistance and fixa-
tion of the transplant to the bone is even more important. At
present, studies are performed on a heterotopic transplanta-
tion or extended cultures in vitro with hyaluronic acid to
address the biomechanical problem. Another alternative is
the establishment of osteochondral transplants, which
consist of artificial cartilage tissue cultured directly on
porous calcium carbonate [23] to achieve a permanent,
solid connection between cartilage and bone tissue. Liga-
ments and menisci are often victims of ambitious sport and
exercise activities and exhibit a poor intrinsic healing
capacity. The transplantation of fibroblast-seeded scaffolds
cultured under specific biomechanical conditions (tensile
strength) and under the influence of growth factors seems
an auspicious alternative to present procedures [24,25].
Further efforts will be directed at the repair of damaged and
degenerated spinal compartments, for example the implan-
tation of cell-gels or the application of growth factors such
as BMPs 2 and 4 to restore intervertebral discs. Muscu-
loskeletal structures such as the joint are a morphological
and functional unit, so pathological changes occurring for
instance during osteoarthritis are never restricted to a single
tissue. For a sustained balance of homeostasis, future
approaches will have to focus on the regeneration of
complex structures with different tissue types.
Genetic engineering
Genetic engineering, a hybrid of tissue engineering and
gene therapy, will give a further stimulus to regenerative
and reparative approaches [26]. The functional properties
of mesenchymal stem and progenitor cells (periosteal cells)
make them ideal candidates for genetic engineering, to
enhance the process of tissue regeneration and repair, and
to deliver essential biological factors to restore and main-
tain tissue homeostasis (Figure 2). Regenerative and anti-
inflammatory potency of the transplant can be achieved by
transferring genes of the transforming growth factor-b
superfamily (such as BMPs or their receptors) [27,28]. The
technique of gene therapy (ex vivo or in vitro) has the par-
ticular advantage that a defined population of cells is
genetically modulated, and the effects and dosage for
optimal differentiation and protection can be controlled.
Important considerations are the stability of gene expres-
sion, immunogenicity of the vector, transfer efficiency,
dependence on cell proliferation and the size of genetic
material transduced. Moreover, plasmid DNA can be deliv-
ered directly from polymer matrices, leading to the efficient
transfection of a large number of cells [29]. The systemic
delivery of therapeutic cells, with emphasis on genetically
modified stem cells addressed to specific ‘homing’ sites
Figure 1
General procedure for engineering of bone and cartilage transplants. 
Figure 2
Tools for tissue engineering.
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Conclusion
The innovative tissue engineering tools have established
tantalizing possibilities for the manipulation of cell destiny in
a predictable way: stem cells with their flexible regenerative
potential, tissue-inductive factors, advanced biomaterials
and gene transfer technologies will dramatically amplify our
therapeutic abilities in treating musculoskeletal disorders
and will break new ground in bioregenerative medicine.
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